Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Common Equity (2017 - 2026)

Denali Therapeutics has reported Common Equity over the past 9 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly Common Equity fell 17.56% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 17.56% year-over-year, with the annual reading at $1.0 billion for FY2025, 17.56% down from the prior year.
  • Common Equity was $1.0 billion for Q4 2025 at Denali Therapeutics, up from $926.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $1.5 billion in Q1 2024 and troughed at $811.3 million in Q3 2022.
  • The 5-year median for Common Equity is $1.0 billion (2022), against an average of $1.1 billion.
  • Year-over-year, Common Equity skyrocketed 113.62% in 2021 and then decreased 29.75% in 2025.
  • A 5-year view of Common Equity shows it stood at $962.3 million in 2021, then increased by 8.33% to $1.0 billion in 2022, then fell by 1.1% to $1.0 billion in 2023, then grew by 19.28% to $1.2 billion in 2024, then dropped by 17.56% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Common Equity are $1.0 billion (Q4 2025), $926.2 million (Q3 2025), and $1.0 billion (Q2 2025).